Skip to content

Mindfulness skills and experiential avoidance as therapeutic mechanisms for treatment-resistant depression through mindfulness-based cognitive therapy and lifestyle modification.

Mauro Garcia-Toro, Alejandra Aguilar-Latorre, Aurora Garcia, Capilla Navarro-Guzmán, Elena Gervilla, Andrea Seguí, Francisco Gazquez, Jose Antonio Marino, Rocío Gómez-juanes, María J Serrano-Ripoll, Bárbara Oliván-Blázquez, Javier García-campayo, Shannon Maloney, Jesus Montero-Marin

Frontiers in Psychology 2023 DOI: 10.3389/fpsyg.2023.1008891 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Secondary analysis of a clinical trial Peer reviewed
Sample size 66
Population Patients with treatment-resistant depression
Interventions Minimal Lifestyle Intervention (MLI) Mindfulness-Based Cognitive Therapy (MBCT) Lifestyle Modification Program (LMP)
Measures Five Facet Mindfulness Questionnaire (FFMQ), Self-Compassion Scale (SCS), Acceptance and Action Questionnaire-II (AAQ-II), Beck Depression Inventory-II (BDI-II)
Topics Depression Meditation
Keywords Intervention Lifestyle modification Mediation
Key findings Mindfulness skills mediated the effect of Mindfulness-Based Cognitive Therapy on depressive symptoms (ab = -4.69, 95% CI -12.93 to -0.32), and reduced experiential avoidance mediated the effect of the Lifestyle Modification Program (ab = -3.22, 95% CI -7.03 to -0.14). The authors suggest that strengthening mindfulness skills and decreasing experiential avoidance may promote recovery in treatment-resistant depression.

Abstract

The COVID-19 pandemic and consequent physical distancing has made it difficult to provide care for those with Treatment-Resistant Depression (TRD). As a secondary analysis of a clinical trial, the aim of this study was to explore potential mechanisms through which three online-delivered approaches, added to treatment as usual, improve depressive symptoms in TRD patients. The three approaches included (a) Minimal Lifestyle Intervention (MLI), (b) Mindfulness-Based Cognitive Therapy (MBCT), and (c) Lifestyle Modification Program (LMP). Sixty-six participants with TRD completed assessments pre-post intervention (mindfulness skills [FFMQ]; self-compassion [SCS]; and experiential avoidance [AAQ-II]) and pre-intervention to follow-up (depressive symptoms [BDI-II]). Data were analyzed using within-subjects regression models to test mediation. Mindfulness skills mediated the effect of MBCT on depressive symptoms (ab = -4.69, 95% CI = -12.93 to-0.32), whereas the lack of experiential avoidance mediated the effect of LMP on depressive symptoms (ab = -3.22, 95% CI = -7.03 to-0.14). Strengthening mindfulness skills and decreasing experiential avoidance may promote recovery in patients with TRD, MBCT, and LMP have demonstrated that they may help increase mindfulness skills and decrease experiential avoidance, respectively. Future work will need to unpick the components of these interventions to help isolate active ingredients and increase optimization.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Cited by 5

Cites 12

and 7 more in the library

Explore topics